Literature DB >> 28832564

Haplotype-based stratification of Huntington's disease.

Michael J Chao1,2, Tammy Gillis1, Ranjit S Atwal1,2, Jayalakshmi Srinidhi Mysore1, Jamshid Arjomand3, Denise Harold4, Peter Holmans4, Lesley Jones4, Michael Orth5, Richard H Myers6, Seung Kwak7, Vanessa C Wheeler1,2, Marcy E MacDonald1,2,8, James F Gusella1,8,9, Jong-Min Lee1,2,8.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by expansion of a CAG trinucleotide repeat in HTT, resulting in an extended polyglutamine tract in huntingtin. We and others have previously determined that the HD-causing expansion occurs on multiple different haplotype backbones, reflecting more than one ancestral origin of the same type of mutation. In view of the therapeutic potential of mutant allele-specific gene silencing, we have compared and integrated two major systems of HTT haplotype definition, combining data from 74 sequence variants to identify the most frequent disease-associated and control chromosome backbones and revealing that there is potential for additional resolution of HD haplotypes. We have used the large collection of 4078 heterozygous HD subjects analyzed in our recent genome-wide association study of HD age at onset to estimate the frequency of these haplotypes in European subjects, finding that common genetic variation at HTT can distinguish the normal and CAG-expanded chromosomes for more than 95% of European HD individuals. As a resource for the HD research community, we have also determined the haplotypes present in a series of publicly available HD subject-derived fibroblasts, induced pluripotent cells, and embryonic stem cells in order to facilitate efforts to develop inclusive methods of allele-specific HTT silencing applicable to most HD patients. Our data providing genetic guidance for therapeutic gene-based targeting will significantly contribute to the developments of rational treatments and implementation of precision medicine in HD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28832564      PMCID: PMC5643960          DOI: 10.1038/ejhg.2017.125

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  30 in total

1.  A novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene.

Authors:  Lance H Rodan; Julie Cohen; Ali Fatemi; Tammy Gillis; Diane Lucente; James Gusella; Jonathan D Picker
Journal:  Eur J Hum Genet       Date:  2016-12       Impact factor: 4.246

2.  Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder.

Authors:  Roy H Perlis; Jordan W Smoller; Jayalakshmi Mysore; Mei Sun; Tammy Gillis; Shaun Purcell; Marcella Rietschel; Markus M Nöthen; Stephanie Witt; Wolfgang Maier; Dan V Iosifescu; Patrick Sullivan; A John Rush; Maurizio Fava; Hans Breiter; Marcy Macdonald; James Gusella
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

3.  Next-generation genotype imputation service and methods.

Authors:  Sayantan Das; Lukas Forer; Sebastian Schönherr; Carlo Sidore; Adam E Locke; Alan Kwong; Scott I Vrieze; Emily Y Chew; Shawn Levy; Matt McGue; David Schlessinger; Dwight Stambolian; Po-Ru Loh; William G Iacono; Anand Swaroop; Laura J Scott; Francesco Cucca; Florian Kronenberg; Michael Boehnke; Gonçalo R Abecasis; Christian Fuchsberger
Journal:  Nat Genet       Date:  2016-08-29       Impact factor: 38.330

4.  A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.

Authors:  Maria Stella Lombardi; Leonie Jaspers; Christine Spronkmans; Cinzia Gellera; Franco Taroni; Emilio Di Maria; Stefano Di Donato; William F Kaemmerer
Journal:  Exp Neurol       Date:  2009-03-13       Impact factor: 5.330

5.  Allele-specific silencing of mutant Huntington's disease gene.

Authors:  Yu Zhang; Joshua Engelman; Robert M Friedlander
Journal:  J Neurochem       Date:  2009-01       Impact factor: 5.372

Review 6.  Huntington disease.

Authors:  Gillian P Bates; Ray Dorsey; James F Gusella; Michael R Hayden; Chris Kay; Blair R Leavitt; Martha Nance; Christopher A Ross; Rachael I Scahill; Ronald Wetzel; Edward J Wild; Sarah J Tabrizi
Journal:  Nat Rev Dis Primers       Date:  2015-04-23       Impact factor: 52.329

7.  Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.

Authors: 
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

8.  Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

Authors:  Edith L Pfister; Lori Kennington; Juerg Straubhaar; Sujata Wagh; Wanzhou Liu; Marian DiFiglia; Bernhard Landwehrmeyer; Jean-Paul Vonsattel; Phillip D Zamore; Neil Aronin
Journal:  Curr Biol       Date:  2009-04-09       Impact factor: 10.834

9.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.

Authors:  Michael E Østergaard; Amber L Southwell; Holly Kordasiewicz; Andrew T Watt; Niels H Skotte; Crystal N Doty; Kuljeet Vaid; Erika B Villanueva; Eric E Swayze; C Frank Bennett; Michael R Hayden; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2013-08-19       Impact factor: 16.971

View more
  14 in total

1.  A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.

Authors:  Chris Kay; Jennifer A Collins; Nicholas S Caron; Luciana de Andrade Agostinho; Hailey Findlay-Black; Lorenzo Casal; Dulika Sumathipala; Vajira H W Dissanayake; Mario Cornejo-Olivas; Fiona Baine; Amanda Krause; Jacquie L Greenberg; Carmen Lúcia Antão Paiva; Ferdinando Squitieri; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2019-11-07       Impact factor: 11.025

2.  Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA.

Authors:  Kyung-Hee Kim; Kawther Abu Elneel; Jun Wan Shin; Jae Whan Keum; David Seong; Seung Kwak; Ramee Lee; James F Gusella; Marcy E MacDonald; Ihn Sik Seong; Jong-Min Lee
Journal:  J Hum Genet       Date:  2019-07-11       Impact factor: 3.172

3.  Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.

Authors:  Sarah R Oikemus; Edith L Pfister; Ellen Sapp; Kathryn O Chase; Lori A Kennington; Edward Hudgens; Rachael Miller; Lihua Julie Zhu; Akanksh Chaudhary; Eric O Mick; Miguel Sena-Esteves; Scot A Wolfe; Marian DiFiglia; Neil Aronin; Michael H Brodsky
Journal:  Hum Gene Ther       Date:  2022-01       Impact factor: 5.695

Review 4.  Huntington's Disease Pathogenesis: Two Sequential Components.

Authors:  Eun Pyo Hong; Marcy E MacDonald; Vanessa C Wheeler; Lesley Jones; Peter Holmans; Michael Orth; Darren G Monckton; Jeffrey D Long; Seung Kwak; James F Gusella; Jong-Min Lee
Journal:  J Huntingtons Dis       Date:  2021

Review 5.  Distribution of the HTT Gene A1 and A2 Haplotypes Worldwide: A Systematic Review.

Authors:  Thays Andrade Apolinário; Dionatan Costa Rodrigues; Mayra Braga Lemos; Carmen Lúcia Antão Paiva; Luciana Andrade Agostinho
Journal:  Clin Med Res       Date:  2020-09-02

Review 6.  Gene targeting techniques for Huntington's disease.

Authors:  Eric Fields; Erik Vaughan; Deepika Tripu; Isabelle Lim; Katherine Shrout; Jessica Conway; Nicole Salib; Yubin Lee; Akash Dhamsania; Michael Jacobsen; Ashley Woo; Huijing Xue; Kan Cao
Journal:  Ageing Res Rev       Date:  2021-06-05       Impact factor: 11.788

7.  Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.

Authors:  Ramita Dewan; Ruth Chia; Jinhui Ding; Richard A Hickman; Thor D Stein; Yevgeniya Abramzon; Sarah Ahmed; Marya S Sabir; Makayla K Portley; Arianna Tucci; Kristina Ibáñez; F N U Shankaracharya; Pamela Keagle; Giacomina Rossi; Paola Caroppo; Fabrizio Tagliavini; Maria L Waldo; Per M Johansson; Christer F Nilsson; James B Rowe; Luisa Benussi; Giuliano Binetti; Roberta Ghidoni; Edwin Jabbari; Coralie Viollet; Jonathan D Glass; Andrew B Singleton; Vincenzo Silani; Owen A Ross; Mina Ryten; Ali Torkamani; Toshiko Tanaka; Luigi Ferrucci; Susan M Resnick; Stuart Pickering-Brown; Christopher B Brady; Neil Kowal; John A Hardy; Vivianna Van Deerlin; Jean Paul Vonsattel; Matthew B Harms; Huw R Morris; Raffaele Ferrari; John E Landers; Adriano Chiò; J Raphael Gibbs; Clifton L Dalgard; Sonja W Scholz; Bryan J Traynor
Journal:  Neuron       Date:  2020-11-26       Impact factor: 18.688

Review 8.  The prospects of CRISPR-based genome engineering in the treatment of neurodegenerative disorders.

Authors:  Jun Wan Shin; Jong-Min Lee
Journal:  Ther Adv Neurol Disord       Date:  2017-11-15       Impact factor: 6.570

9.  Population-specific genetic modification of Huntington's disease in Venezuela.

Authors:  Michael J Chao; Kyung-Hee Kim; Jun Wan Shin; Diane Lucente; Vanessa C Wheeler; Hong Li; Jared C Roach; Leroy Hood; Nancy S Wexler; Laura B Jardim; Peter Holmans; Lesley Jones; Michael Orth; Seung Kwak; Marcy E MacDonald; James F Gusella; Jong-Min Lee
Journal:  PLoS Genet       Date:  2018-05-11       Impact factor: 5.917

10.  Targeted gene silencing in the nervous system with CRISPR-Cas13.

Authors:  Jackson E Powell; Colin K W Lim; Ramya Krishnan; Tristan X McCallister; Christian Saporito-Magriña; Maria A Zeballos; Garrett D McPheron; Thomas Gaj
Journal:  Sci Adv       Date:  2022-01-19       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.